(a) [CFU/cell] vs. -mAb, Cetuximab, and Trastuzumab (total tumor).

(b) [CFU/cell] vs. -mAb, Cetuximab, and Trastuzumab (gentamycin treated tumor).

(c) [CFU/g] vs. -mAb, Cetuximab, and Trastuzumab (liver).

(d) [CFU/g] vs. -mAb, Cetuximab, and Trastuzumab (spleen).

- mAb
- Cetuximab
- Trastuzumab

Statistical significance:
- * P < 0.05
- ** P < 0.01
- *** P < 0.001
- ns: not significant